AUS
NZ
UK
CA
USA
IND
Highlights
- Mayne Pharma shares dropped nearly 30% amid acquisition uncertainty
- Cosette Pharmaceuticals raises concerns over financial and legal issues
- Potential impact on ASX200 biotech sector and investor sentiment
Mayne Pharma Group (ASX:MYX) saw its shares tumble by almost 30% after uncertainty arose around its proposed $672 million acquisition by US-based Cosette Pharmaceuticals. The dramatic shift follows concerns raised by Cosette about what it describes as a “material adverse change” in Mayne’s financial condition—posing a significant challenge to the February-announced takeover deal.
At 10:38am AEST, Mayne Pharma’s share price had dropped by 29.78%, trading at $4.55. The decline followed Cosette’s formal communication dated 17 May, where it cited a mix of financial underperformance, ongoing litigation, and regulatory scrutiny as factors triggering its concerns.
Specifically, Cosette pointed to Mayne's disappointing trading results since the April earnings report, ongoing legal proceedings involving US-based TherapeuticsMD (NASDAQ:TXMD), and a recent letter from the US Food and Drug Administration (FDA). The FDA alleged that Mayne may have misrepresented safety information in promotional materials for an oral contraceptive product.
In response, Mayne denied these claims in a letter dated 20 May. Nevertheless, the acquisition’s fate now hangs in the balance, as both companies are locked in a mandatory 10-business-day consultation period. If the concerns remain unresolved, Cosette could formally exit the agreement and abandon the acquisition entirely.
This development adds volatility to the Australian biotech landscape, especially within the ASX200 index. Investors tracking the index may want to observe how such news can ripple across related healthcare and pharmaceutical stocks.
Additionally, in a climate where income-focused strategies are gaining attention, especially amid interest rate fluctuations, some investors are exploring established ASX dividend stocks.
While the coming days will clarify the direction of the Mayne-Cosette transaction, the current turbulence highlights the sensitivity of M&A deals to financial performance and regulatory scrutiny. The outcome may influence sentiment across the sector, particularly for biotech firms operating under similar oversight and litigation environments.
Stay tuned as the consultation period unfolds and shapes the next chapter for Mayne Pharma and its standing within the ASX200 landscape.
